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Poliovirus (PV) is able to establish persistent infections in human neuroblastoma IMR-32 cells [Colbe`re-Garapin et al.
(1989) Proc. Natl. Acad. Sci. USA 86, 7590]. During persistent infection, PV mutants are selected that display substitutions of
residues in regions of the capsid known to interact with the PV receptor (PVR), a glycoprotein of the immunoglobulin
superfamily. The mechanism of persistent infection in IMR-32 cells may therefore involve the selection of mutant PVRs. To
test this hypothesis, the sequences of the PVR mRNAs in uninfected IMR-32 cells and in two independent IMR-32 cell
cultures persistently infected with the Mahoney strain of PV type 1 (PV1/Mahoney) were determined. The PVR mRNA
population of uninfected cells was homogeneous, and no mutation was repeatedly found, whereas that of persistently
infected cells displayed missense mutations. Particular mutations were repeatedly detected, and all of them mapped to the
N-terminal domain of PVR (domain 1), which interacts directly with PV. These mutations generated several types of PVR
variants with the following substitutions: Ala673Thr alone, Ala673Thr associated with Gly393Ser, and Arg1043Gln.
Functional analysis of PVR in murine LM cells, stably expressing each of the PVR forms, showed that the PVR forms selected
during persistent infection conferred on LM cells partial resistance to PV1/Mahoney-induced lysis. Although adsorption onto
PVR seemed to be independent of the PVR form, an analysis of the conformational changes of the capsid during the early
steps of the PV cycle provided evidence that the Ser39/Thr67 and Gln104 substitutions almost halved the conversion of 160S
infectious particles into 135S A particles associated with the PV–PVR interaction. Altogether, these findings indicate that during
persistent infection, specific mutations were selected in the domain 1 of PVR and that these mutations increased the resistance
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INTRODUCTION
An investigation of persistent infections in cell cultures
leads to a better understanding of virus–cell interactions
and improves our knowledge of the molecular factors
involved in the establishment and maintenance of these
infections. Many cytolytic RNA viruses are able to infect
cultured cells persistently. Studies of the mechanisms of
these models of viral infection have shown that there is
frequently a coevolution of mutant cells with higher re-
sistance to viral infection and of virus variants with in-
creased virulence. In models of persistent infection with
reovirus, murine hepatitis virus (MHV), foot-and-mouth
disease virus (FMDV), and murine encephalomyocardi-
tis, coevolution of cell and virus involves steps in the
process of viral entry (Baer et al., 1999; Chen and Baric,
996; Dermody et al., 1993; Martin-Hernandez et al., 1994;
Pardoe et al., 1990; Sawicki et al., 1995). We have devel-
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ped several models of persistent infections with polio-
irus (PV), in particular, in neuroblastoma IMR-32 cells,
uman cells of neuronal origin, and primary cultures of
uman fetal brain cells (Colbe`re-Garapin et al., 1989;
avio et al., 1996), but the mechanisms by which these
ersistent infections occur are not yet known.
Studies of persistent infection with PV, a member of
he Picornaviridae family, are facilitated by its structure
nd its multiplication cycle being well characterized
Wimmer et al., 1993). This small virus has a single-
tranded RNA genome of positive polarity, enclosed in an
cosahedral capsid composed of 60 copies of each of the
our viral proteins (VP1–4). The atomic structure of the
ahoney strain of PV type 1 (PV1/Mahoney) has been
etermined (Filman et al., 1989; Hogle et al., 1985): the
ajor capsid proteins VP1, VP2, and VP3 share a similar
tructure constituted of an eight-stranded b-barrel core
flanked by terminal extensions. The N-terminal exten-
sions, with the small internal protein VP4, create a net-
work on the internal surface of the capsid, and this
network probably stabilizes the native virion. Surround-
ing each of the fivefold axes of symmetry, formed by five
copies of the capsid protein VP1, is a deep cleft, called
the canyon. The canyon contains the site for PV receptor
0042-6822/00 $35.00
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caniello, 1994, 1995; He et al., 2000; Xing et al., 2000). On
binding to PVR, the PV capsid undergoes a conforma-
tional alteration that reduces its sedimentation coeffi-
cient from 160S to 135S (Lonberg-Holm et al., 1975). The
ltered 135S particles, named A particles, have external-
zed VP4 and the N-terminus of VP1 (Fricks and Hogle,
990). They are representative of the conformational
ransitions of the capsid induced by the PVR, although
heir role in viral uncoating is still debated (Arita et al.,
998; Belnap et al., 2000a; Dove and Racaniello, 1997).
Most reference PV strains, including PV1/Mahoney,
are capable of establishing persistent infections in hu-
man neuroblastoma IMR-32 cells, whereas the same
strains are fully lytic in human epidermoid HEp-2 cells
(Colbe`re-Garapin et al., 1989). This suggests that the cell
phenotype plays a crucial role in persistent infection.
Furthermore, IMR-32 cells cured of persistent infection
are more resistant to PV infection than the original
IMR-32 cell line and do not display cytopathic effect
(CPE) on secondary infection (our unpublished results),
suggesting that during persistent infection, cell variants
are selected. Viral variants (PVpi) with novel phenotypic
properties are also selected during the persistent infec-
tion of neuronal cells (Pelletier et al., 1991). In particular,
PVpi exhibit a modified cell tropism. They readily estab-
lish persistent infections in the human non-neural HEp-2
cell line, in contrast to the parental reference PV strains
(Pelletier et al., 1991). In this model, viral and cellular
determinants involved in persistence affect PV–PVR in-
teractions (Calvez et al., 1995a; Duncan et al., 1998;
Pelletier et al., 1998).
During persistent infections of either neuroblastoma
cells or primary cultures of fetal brain cells with PV1/
Mahoney, mutations are selected at two positions, in
particular, in capsid proteins between 2 and 6 weeks
after infection: one at position 95 of VP1 (Pro3Ser) and
the other at position 142 of VP2 (His3Tyr) (Calvez et al.,
1995b; Couderc et al., 1994; Pavio et al., 1996). Interest-
ingly, these two residues were also selected in PV1/
Mahoney variants adapted to grow on cells expressing
mutant forms of the PVR (Colston and Racaniello, 1995).
Residue 95 of VP1 is located in the B-C loop, a well-
exposed sequence on the virion surface near the fivefold
axis, and virions having this mutation convert to the 135S
form more readily than PV1/Mahoney in vitro (Wien et al.,
1997). It was recently suggested that alterations in the
B-C loop affect cell entry steps downstream from recep-
tor binding (Belnap et al., 2000b). Residue 142 of VP2 is
located on the rim of the canyon in the receptor binding
site (Belnap et al., 2000b; He et al., 2000). The His3Tyr
substitution at this position has negligible effects on the
structure of the virion but may modify the contact point
with PVR (Colston and Racaniello, 1995; Wien et al.,
332 PAV1997). The selection of these mutations both in persis-
tently infected neuronal cells and in cells expressingmutant receptors suggests that interactions between PV
and its receptor play an important role in the mechanism
of PV persistence in this model.
The PVR, also named CD155, is a member of the
immunoglobulin superfamily of proteins (Koike et al.,
1990; Mendelsohn et al., 1989). Its cellular function is not
yet known. PVR is predicted to contain three extracellular
Ig-like domains in the order V-C2-C2, followed by a trans-
membrane region and a cytoplasmic tail. In HeLa cells,
two different bases (G and A) have been found at nucle-
otide position 199, resulting in an Ala or a Thr residue at
amino acid position 67 in the PVR. It was suggested that
this difference in PVR mRNA of HeLa cells may be due to
an allelic difference (Koike et al., 1990). Four isoforms are
produced by alternative splicing, of which only two, PVRa
and PVRd, are functional membrane-bound PVRs (Koike
et al., 1990). The N-terminal V-like Ig domain (domain 1)
appears to contain the binding site for PV (Aoki et al.,
1994; Bernhardt et al., 1994; Koike et al., 1991; Morrison et
al., 1994). The three-dimensional structure of PVR bound
to PV has been recently determined by cryoelectron
microscopy (Belnap et al., 2000a,b; He et al., 2000; Xing
et al., 2000). PVR domain 1 is necessary and sufficient for
the early steps of the PV cycle. Although the PVR do-
mains 2 and 3 do not directly interact with the PV particle,
they seem to be important for efficient PVR function. In
addition, cells expressing PVR with mutations in the C0
edge of the domain 1 do not develop CPE during PV
infection, suggesting that PV-induced CPE may result
from PV–PVR interactions (Morrison et al., 1994). These
data suggest that the mechanism of persistent infection
in neuroblastoma cells may involve the selection of mu-
tated PVRs.
To investigate this hypothesis, the sequences of PVR
mRNAs in two independent neuroblastoma IMR-32 cell
cultures persistently infected with PV1/Mahoney were
determined. Missense mutations were repeatedly iden-
tified in the region encoding domain 1 of the PVR. Their
effects on cell resistance to PV-induced lysis and on the
kinetics of PV multiplication were then studied in stable
murine LM cell lines expressing mutated PVR. PV bind-
ing onto these cells and the following conformational
transitions of the viral capsid were also investigated. The
results are discussed in view of the position of the
mutations on the structure of PVR domain 1.
RESULTS
Selection of mutations in the mRNA of PVR during
persistent infection
To investigate whether missense mutations are se-
lected in the PVR expressed in persistently infected neu-
roblastoma cells, IMR-32 cells were infected with PV-1/
Mahoney, and two independent cultures, called IMR/KK3
AL.and IMR/KK5, were maintained for 2.5 months after in-
fection. Total RNA was extracted from both persistently
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The mRNA of the PVRa isoform was amplified in three
ragments by RT–PCR, with specific oligonucleotides as
escribed under Materials and Methods. Each fragment
as cloned, and the sequence of 10 clones of each was
etermined.
The PVR sequence expressed in IMR-32 cells at pas-
age 13 was identical to the published sequence (Koike
t al., 1990; Mendelsohn et al., 1989) for all of the cDNA
lones covering the 59, central, and 39 parts of the PVR-
ncoding region, with the exception of one mutation at
ucleotide 173 (T3C) found in only a single clone and
esulting in a Val-to-Ala substitution at position 58 of the
mino acid sequence (data not shown). All of the 10
lones corresponding to the first domain of PVR exhib-
ted a G at position 199, resulting in an Ala at position 67
f the amino acid sequence (Fig. 1). Two different bases
G and A) have been reported at this nucleotide position
n the published sequences (Koike et al., 1990; Mendel-
ohn et al., 1989), resulting in an Ala and a Thr residue,
respectively, at position 67 in the PVR sequence. There-
fore uninfected IMR-32 cells expressed only one of these
allelic forms. Despite IMR-32 cells being tumor cells
(Tumilowicz et al., 1970), only one dominant PVR form
FIG. 1. Localization of missense mutations identified in domain 1 of PV
obtained after amplification by RT–PCR of PVR domain 1 mRNA from un
IMR-KK5, were sequenced. The number of clones corresponding to each
bold. p, Several substitutions were found in other loci than those indicate
EXPRESSION OF MUTATwas found. To confirm this homogeneity and because we
could not clone IMR-32 cells, sequences were deter-mined at a later passage for IMR-32 cells (passage 55).
The same PVR dominant form was found, and the muta-
tion at nucleotide position 173 was not found in this
second series of 10 clones.
The comparison of PVR mRNA sequences isolated
from persistently infected IMR/KK3 and IMR/KK5 cells
with that from IMR-32 cells showed that PVR mRNA from
persistently infected cells carried missense mutations in
the region encoding domain 1 of PVR (Fig. 1). No muta-
tions were repeatedly found in domains 2 or 3 or in the
transmembrane or cytoplasmic regions of the PVR in
most of the clones. One missense mutation was found in
the transmembrane domain of only one clone isolated
from IMR/KK3 cells, and another one was found in the
cytoplasmic domain of one clone isolated from IMR/KK5
cells (data not shown).
Among the 10 clones corresponding to the first domain
of the PVRs expressed in IMR/KK3, two had the substi-
tution at nucleotide 199 that results in an Ala-to-Thr
change at position 67 (Fig. 1), generating the other allelic
form found in HeLa cells (Koike et al., 1990; Mendelsohn
et al., 1989); four had two substitutions, one at nucleotide
115 causing a Gly-to-Ser change at residue 39 and the
other at nucleotide 199 causing the Ala-to-Thr change at
ssed in IMR-32 cell lines persistently infected with PV. Ten cDNA clones
IMR-32 cells and from PV persistently infected cell lines, IMR-KK3 and
ce is indicated. Nucleotide and amino acid substitutions are indicated in
ver, each was found only in a single clone.
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at the same positions as those found in IMR/KK3: four
clones had the substitution causing an Ala-to-Thr change
at position 67, and two clones had both substitutions
causing the Gly-to-Ser change at residue 39 and the
Ala-to-Thr change at position 67 (Fig. 1). Several substi-
tutions were found in other loci of PVR domain 1 of
IMR/KK5 cells, but each was found in only one clone
(data not shown). Because the relevance of mutations
detected only once is unclear, we chose to study further
only the mutations detected in several clones.
These results indicated that PVR mRNA from unin-
fected IMR-32 cells was homogeneous and that during
persistent infections of IMR-32 cells with PV, particular
mutations were expressed in the PVR mRNA. One of
them corresponds to an allelic variation. Interestingly, all
of these mutations were located in the region encoding
domain 1 of the PVR, the domain that interacts with the
PV particle.
Isolation of murine cells transformed by the PVR
cDNAs and PVR expression
To examine whether mutated PVRs expressed in per-
sistently infected cells play a role in PV persistence,
mutated PVR forms were expressed in murine LM cells
that do not have the PVR gene. Mutations corresponding
to the PVR forms identified in IMR/KK3 and IMR/KK5
were introduced by site-directed mutagenesis into PVR
cDNA. The plasmid pSV2-PVRa (Koike et al., 1990), con-
aining the cDNA encoding PVRa expressed in IMR-32
cells (PVRIMR), was used to obtain three different PVRs:
PVR-Thr67 with a threonine residue at position 67, PVR-
Ser39/Thr67 with a serine residue at position 39 and a
threonine residue at position 67, and PVR-Gln104 with a
glutamine residue at position 104. All of the PVR cDNAs
were used to establish stable transformant LM cell lines
expressing the various PVR forms, as described under
Materials and Methods. PVR-expressing cells were
stained by immunofluorescence with anti-PVR antibodies
and sorted by fluorescence activated cell sorting (FACS).
Sorting was performed two or three times for each cell
culture, until 95–99% of the sample was transformant LM
cells expressing PVR. There were some differences in
the level of PVR expression on the cell surface between
the different cell lines, as previously observed (Morrison
et al., 1994). The level of PVR expression on the cell
surface of LM/PVRIMR was similar to that on the cell
surface of the fully permissive HEp-2 cells, which are
commonly used to amplify PV. The level of PVR expres-
sion on the cell surface of LM/PVR variants was between
one third and two thirds of that on LM/PVRIMR. The pres-
nce of mutations in the PVR mRNA of these cells was
erified. The phenotype of LM/PVR cells, evaluated by
334 PAVmmunofluorescence with anti-PVR antibodies and FACS
nalysis, was stable for 2 months. We thus obtained four
p
mtable LM cell lines, each expressing a different form of
VR, called LM/PVRIMR, LM/PVR-Thr67, LM/PVR-Ser39/
Thr67, and LM/PVR-Gln104. Cell clones expressing each
of the PVR forms were also isolated.
Resistance of cells expressing mutant PVRs to
PV-induced lysis
To test whether mutated PVRs affect CPE induced by
PV, LM cell lines expressing PVRIMR or PVR variants were
infected with PV-1/Mahoney. The percentage of surviving
cells 28 h after infection was determined. To ensure that
each cell was infected independently of the level of PVR
expression on the cell surface, cell cultures were in-
fected at a high m.o.i. [10 TCID50 (50% tissue culture
infectious doses)/cell]. As shown in Fig. 2, a larger per-
centage of LM/PVR-Ser39/Thr67 and LM/PVR-Gln104
cells (nearly 90%) than LM/PVRIMR cells (56%) survived
PV-1/Mahoney infection. LM/PVR-Thr67 had an interme-
diate phenotype with 70% cell survival. These results
were repeatedly obtained and confirmed at an m.o.i. of
0.1 TCID50 per cell (data not shown). Similar differences
ere detectable up to 3 days postinfection (p.i.), after
hich time the infection led to the selection of a few
VR-negative cells, preventing longer experiments. Com-
arable results were also obtained with LM/PVR cell
lones expressing the same PVR forms (data not shown).
To detect possible serotype-specific modulation of PV
nteractions with mutant PVRs, as previously observed
Harber et al., 1995), similar experiments were performed
ith the PV type 3 strain Leon (PV3/Leon). Again, as in
he case of PV1/Mahoney, a larger percentage of LM/
VR-Ser39/Thr67 and LM/PVR-Gln104 cells than LM/
VRIMR cells survived infection (data not shown).
To test whether mutations selected in PV1/Mahoney
uring persistent infection of IMR-32 cells could com-
FIG. 2. Percentage of LM/PVR cells surviving after infection with PV.
LM/PVR cell lines were infected at an m.o.i. of 10 TCID50/cell with
PV1/Mahoney, and the percentage of surviving adherent cells was
determined after 28 h of incubation. Each value is the average of two
independent experiments. The SEM values are indicated.
AL.ensate for the resistance to cell lysis conferred by
utant PVRs, cell clones expressing the various PVR
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pforms were infected with the PV1/Mahoney mutants hav-
ing either a Pro-to-Ser substitution at position 95 of VP1
(Mah-KKVP1S95), or a His-to-Tyr substitution at position
142 of VP2 (Mah-KKVP2Y142) (Couderc et al., 1994). The
mutant Mah-KKVP1S95 was slightly more lytic in LM/
PVRIMR cells than the mutant Mah-KKVP2Y142 and PV1/
ahoney. With all three viruses, cell clones expressing
utant PVRs were more resistant to lysis than LM/PVRIMR
cells (not shown).
Therefore, expression of the mutant PVR forms present
in persistently infected neuroblastoma cell cultures con-
ferred on cells a partial resistance to PV-induced lysis.
Poliovirus multiplication in PVR mutant cell lines
To investigate the effect of PVR mutations on the rep-
lication of PV, the time course of virus production was
analyzed in LM cell lines expressing each of the PVR
forms after infection with PV-1/Mahoney at an m.o.i. of 10
TCID50/cell. The amounts of cell-associated and extra-
cellular infectious particles were determined by TCID50
assay (Fig. 3). During the eclipse phase, the loss of
infectivity appeared maximal 2 h p.i. in LM/PVRIMR and in
M/PVR-Thr67 and LM/PVR-Gln104 cells. However, it
as slightly less pronounced in these two cell lines
xpressing variant PVR. In LM/PVR-Ser39/Thr67 cells,
he loss of infectivity seemed to be delayed with a max-
mum at 4 h p.i. From 6 h p.i., extracellular viral yields
ere similar in all cell lines. PVR mutations might slightly
ffect the early steps of infection without affecting viral
ields.
The fact that PV1/Mahoney-inoculated cells were truly
nfected was confirmed by immunofluorescence. Viral
ntigen, which was not detected at 2 h p.i. in any of the
ell lines, was intensely stained 24 h p.i. in 41, 35, 49, and
0% of infected LM/PVRIMR, LM/PVR-Thr67, LM/PVR-
FIG. 3. Single-cycle growth curves of PV1/Mahoney in LM/PVR cell li
ere harvested separately at the indicated times p.i., and then cell-ass
oint represents the mean of two separate experiments.
EXPRESSION OF MUTATSer39/Thr67, and LM/PVR-Gln104 cells, respectively (not
shown). This viral antigen therefore corresponded tonewly synthesized viral proteins. Thus cells expressing
mutant PVRs were not resistant to infection despite their
partial resistance to PV-induced lysis. We then studied
PV–PVR interactions further.
PVR mutations do not affect PV binding to cells
To determine the effects of PVR mutations on the
efficiency of virus adsorption, we examined the binding
of radiolabeled PV-1/Mahoney to LM/PVRIMR and LM/PVR
variant cell lines. Untransfected LM cells were used as a
negative control. Because PV undergoes a conforma-
tional transition when it interacts with PVR at 37°C (Go-
mez Yafal et al., 1993), the binding assays were per-
formed at 4°C overnight. LM/PVRIMR cells were incubated
ith radiolabeled virus at an m.o.i. of 40 TCID50/cell. The
umber of cells was adjusted so as to have identical
umbers of PVR molecules available in all assays. Under
hese conditions, the adsorption of virus onto cells ex-
ressing the various PVR forms was similar and reached
bout 75% of the input virus (Fig. 4). When the adsorption
eriod was shortened (150 min), the adsorption of virus
as similar at the surface of LM/PVRIMR and LM/PVR-
Gln104 cells (26% of the input virus) and was slightly
higher in the case of LM/PVR-Thr67 and LM/PVR-Ser39/
Thr67 (30 and 36% of the input virus, respectively). These
results indicate that the variant PVR forms had an effi-
ciency of PV binding at least as high as that of PVRIMR.
PVR mutations affect conformational transitions
mediated by PVR
To investigate in more detail the early steps of PV
infection in cells expressing mutant PVRs, we studied the
conformational transition mediated by the PVR, from
160S native particles to 135S particles (Fricks and Hogle,
lls were infected at an m.o.i. of 10 TCID50/cell. Cells and supernatants
and extracellular virus yields were determined by TCID50 assay. Each
335LIOVIRUS RECEPTORSnes. Ce
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incubating radiolabeled PV-1/Mahoney with LM/PVR
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3 IO ETcells. Under these conditions, the binding efficiency of
PV1/Mahoney was similar on the four cell lines. Confor-
mational transitions were then induced by incubation at
37°C for 15 min. The distribution patterns of 160S and
FIG. 4. PV binding onto LM/PVR cell lines. Adsorption was carried
out overnight at 4°C with [35S]methionine-radiolabeled PV-1/Mahoney
as described under Materials and Methods. PVR-negative LM cells
were used as a negative control. Each value is the average of two
independent experiments. The SEM values are indicated.
FIG. 5. PV conformational alteration assays in LM/PVR cell lines.
ynchronized at 4°C, and then infected cells were switched to 37°C fo
36 PAVedimentation through a 15–30% (wt/vol) sucrose gradient. The 135S/160S alte
he area under the 160S peak is indicated.135S particles were analyzed by sucrose gradient ultra-
centrifugation, and the transitions were evaluated as the
ratio between areas under the 135S and 160 peaks (Fig.
5). In LM cells expressing PVR, the 135S/160S ratios for
LM/PVR-Gln104 and LM/PVR-Ser39/Thr67 were almost
half that for LM/PVRIMR. The ratio for LM/PVR-Thr67 was
similar to that for LM/PVRIMR. Similar differences were
btained when conformational alterations were induced
or 40 min (data not shown). This indicates that the major
VR forms isolated from persistently infected IMR/KK3
ells (i.e., PVR-Gln104 and PVR-Ser39/Thr67) were less
fficient than PVRIMR in triggering the transitions of PV1/
Mahoney.
DISCUSSION
During persistent PV infection of human cells of neu-
ronal origin, PVpi mutated in regions known to interact
with PVR are selected (Borzakian et al., 1993; Couderc et
al., 1994; Pavio et al., 1996). This led us to investigate
whether the mechanism of PV persistence in these cells
involves the selection of mutant PVR. The sequences of
the PVR mRNA in two neuroblastoma IMR-32 cell cul-
n of cells with [35S]methionine-radiolabeled PV-1/Mahoney was first
n. The conversion of 160S virions to 135S particles was analyzed after
AL.Infectio
r 15 miration ratio corresponding to the area under the 135S peak divided by
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ED POtures (IMR/KK-3 and IMR/KK-5) persistently infected with
PV1/Mahoney for 2.5 months were compared with that in
uninfected IMR-32 cells. In uninfected cells, at two dif-
ferent passages, all sequences of the clones corre-
sponding to the first domain of PVR cDNA (20 in total),
except one with a missense mutation at nucleotide po-
sition 173, were identical to the published sequence,
with a G at nucleotide position 199 of the mRNA, leading
to an Ala at position 67 of the amino acid sequence
(Koike et al., 1990; Mendelsohn et al., 1989). The se-
quences encoding the other domains of the PVR in
IMR-32 cells were identical to those of HeLa cells (Koike
et al., 1990; Mendelsohn et al., 1989). Thus PVR mRNAs
were homogeneous and expressed only one of the two
allelic forms found in HeLa cells (Koike et al., 1990). In
contrast, the PVR mRNA population of persistently in-
fected IMR-KK3 cultures was heterogeneous: some mis-
sense mutations were repeatedly detected, all of which
mapped in the first domain of PVR. These mutations lead
to (1) the other PVR allelic form with the substitution
Ala673Thr alone and (2) two types of mutant PVRs, one
with the substitutions Ala673Thr associated with
Gly393Ser, and the other with Arg1043Gln. Remark-
ably, both the substitution Ala673Thr alone and the
double substitution Ala673Thr and Gly393Ser were
also selected in an independent persistently infected cell
culture (IMR-KK5).
The selection of mutations in the domain interacting
with PV suggests that the virus is responsible for this
selection. There are at least two possible, nonexclusive
explanations for the rapid emergence of these mutations:
they may already be present in a very small minority of
cells in the cell population before infection and would not
have been detected in the two series of 10 cDNA clones
sequenced at passages 13 and 55, respectively, or they
may be induced by the persistent PV infection. The sec-
ond of these possibilities has previously been suggested
in the case of persistent FMDV infections in vitro (Martin-
Hernandez et al., 1994).
Functional PVR analysis in stable LM cell lines ex-
pressing PVR variants showed that cells expressing
PVR-Thr67, PVR-Ser39/Thr67, or PVR-Gln104 were more
resistant than cells expressing PVRIMR to PV1/Mahoney-
and PV3/Leon-induced lysis. This was also observed
with PV1/Mahoney mutants having either a Pro-to-Ser
substitution at position 95 of VP1 or a His-to-Tyr substi-
tution at position 142 of VP2 (not shown). Although the
role of intracellular factors specific to neuroblastoma
cells cannot be excluded, these results seem to indicate
that PVR mutations selected in persistently infected neu-
roblastoma cells contribute to the resistance of these
cells to PV-induced lysis. It is therefore probable that
these mutations were selected because they conferred
this resistance. PV entry into the cell via mutant recep-
EXPRESSION OF MUTATtors may reduce or delay the initiation of CPE. These
results are in accordance with a previous study suggest-ing that PV-induced CPE may result from PV–PVR inter-
actions (Morrison et al., 1994). Because mutations in the
PV capsid are selected during the first weeks of the
persistent infection in IMR-32 cells (Calvez et al., 1995b),
and two of them confer adaptation to mutant receptors
(Colston and Racaniello, 1995), it is likely that PVR mu-
tations were selected early during infection. Thus PVR
mutations are probably not the most important factor at
the time of infection, when IMR-32 cells expressed
PVRIMR conferring a high susceptibility to PV, but may
contribute to the mechanism of persistent infection in the
weeks after infection.
The partial resistance of LM cells expressing PVR
variants was not associated with a decrease in PV yields,
indicating that PV growth and liberation were not af-
fected by the mutant PVRs, and that these processes
could occur despite delayed cell lysis. There have been
similar observations in the HEp-2 cell model of persis-
tent infection (Calvez et al., 1995a) and in murine trans-
ormant cells expressing PVR molecules mutated on the
0 edge (Morrison et al., 1994). In an attempt to under-
stand how virus–receptor interactions modulate PV-in-
duced lysis, we studied the early steps of the viral cycle
involving PVR, in the various LM/PVR cell lines. Binding
experiments suggest that PV adsorption onto mutant
PVRs is not affected. The analysis of postbinding confor-
mational changes mediated by mutated PVRs showed
that the Ser39/Thr67 and Gln104 substitutions almost
halved the efficiency of the 160S-to-135S alteration. Al-
though the role of 135S A particles is still unclear, their
formation is often associated with virus uncoating (Bel-
nap et al., 2000a; Curry et al., 1996).
The selection of PVR mutants conferring a less effi-
cient PV particle alteration is in accordance with the
selection of PVpi with an enhanced particle alteration
(Pelletier et al., 1998) in such a way that they may com-
pensate mutant PVR defects. The residue Thr67 alone,
corresponding to one of the allelic forms in HeLa cells
(Koike et al., 1990), did not seem to affect the formation of
135S A particles. This residue also had a less significant
effect on cell resistance to lysis. Possibly, the transition
assays may not be sensitive enough to reveal very small
differences in the efficiency of conformational modifica-
tions, such as that which may exist between PVRIMR and
VR-Thr67.
The sites of the substitutions in the structure of PVR
omain 1 (Morrison et al., 1994) may identify residues
nvolved in PV–PVR interactions (Fig. 6). Residue Ser39 is
ocated in b-strand A9, which has not been identified as
region of direct contact with PV (Aoki et al., 1994;
Belnap et al., 2000b; Bernhardt et al., 1994; He et al.,
000; Morrison et al., 1994; Xing et al., 2000). Residue
hr67, in b-strand C, is adjacent to amino acids 68–72,
which were found to make contact with the virus (He et
337LIOVIRUS RECEPTORSal., 2000). Residue Gln104 is located in the D-E loop,
which could interact with the virus (Aoki et al., 1994;
2
c
s
a
w
G
e
G
t
l
i
t
l
l
1
a
m
s
IO ETBelnap et al., 2000b; Bernhardt et al., 1994; He et al.,
000; Morrison et al., 1994). Furthermore, Asn105, adja-
ent to Gln104, carries a carbohydrate chain that pre-
ents steric hindrance for PV attachment (Bernhardt et
l., 1994). Despite their proximity to regions in contact
ith the viral surface, neither residue Thr67 nor residue
ln104 was found to affect PV binding. Our results, how-
ver, identified three residues: the pair Ser39/Thr67 and
ln104, involved in the conformational changes leading
o 135S A particles.
Our results indicate that specific mutations are se-
ected in the first domain of the PVR during the persistent
nfection of human neuroblastoma cells. These muta-
ions conferred on cells an increased resistance to cell
FIG. 6. Structural model of PVR domain 1 showing amino acid
substitutions selected in PV persistently infected IMR-32 cell lines. The
structure of domain 1 (residues Val29 to Leu142) was adapted from He
et al. (2000) (PDB ID: 1DGI) by adding the backbone and side chain
atoms with programs Midas-Plus (Ferrin et al., 1988) and Sybyl (Tripos,
Inc.). The ribbon diagram was calculated with Molscript (Kraulis, 1991)
and rendered with Raster3D (Merritt and Murphy, 1994). The b-strands
are labeled with uppercase letters, and the substituted amino acids are
represented as black, numbered spheres.
338 PAVysis, which may give them a selective advantage during
ong-term infections. This resistance correlated with
n
1poorly efficient transition processes. Neuroblastoma
cells probably coevolve with the virus during persistent
infection. Such coevolution has been observed in persis-
tent infections with several other RNA viruses (Chen and
Baric, 1996; Dermody et al., 1993; Martin-Hernandez et
al., 1994), but it seems to occur later in this PV model
than in that of FMDV (Martin-Hernandez et al., 1994), in
which it occurs in the first hours of infection. The emer-
gence of mutant PVRs in persistently infected cells fur-
ther reveals the diversity of the mechanisms underlying
PV persistence in different cell lines: down-regulation of
PVR expression, poorly efficient host-cell shutoff, and
viral determinants of the capsid (Borzakian et al., 1992;
Carp, 1981; Duncan et al., 1998; Kaplan and Racaniello,
1991; Lloyd and Bovee, 1993). The neuroblastoma cell
model may be particularly valuable for investigating the
way in which PV induces CPE and cell lysis. The cas-
cade of events after the interaction of PV with its receptor
and their involvement in these phenomena remain to be
investigated.
MATERIALS AND METHODS
Cells and virus
Human neuroblastoma IMR-32 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal calf serum (FCS). Murine thymidine kinase-
negative LM cells, which do not have the PVR gene, its
derivatives, and HEp-2 cells were grown in DMEM con-
taining 10% newborn calf serum. The neurovirulent PV
type 1 strain Mahoney (PV1/Mahoney), Mahoney mu-
tants Mah-KKVP1S95 and Mah-KKVP2Y142 (Couderc et al.,
994), and the PV type 3 strain Leon (PV3/Leon) were
mplified on HEp-2 cells, and viral titers were deter-
ined on these cells by measuring TCID50. Two indepen-
dent persistently infected cultures, IMR/KK-3 and IMR/
KK-5, were established after infection of IMR-32 cells
with PV1/Mahoney at an m.o.i. of 10 TCID50/cell at 37°C.
Cells were grown in DMEM with 2% FCS for the first
week p.i. and thereafter in DMEM with 10% FCS. The
culture medium was changed weekly until the culture
reached confluence. Cells were then trypsinized and
divided once per week.
RNA isolation, RT–PCR, and cDNA cloning and
sequencing
Total RNA was isolated from uninfected IMR-32 cells
and from IMR/KK-3 and IMR/KK-5 cells at 2.5 months
after PV1/Mahoney infection (four to six passages), using
the RNA PLUS kit (Bioprobe, Montreuil-sous-Bois,
France). RNA was precipitated twice with isopropanol
and stored at 270°C. PVRa mRNAs were reverse tran-
cribed as three fragments using specific primers an-
AL.ealing at nucleotide (nt) positions 696–723 (fragment 1),
157–1175 (fragment 2), and 1296–1311 (fragment 3). Re-
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ED POverse transcriptions were performed as follows: total
RNA (5 mg) and 15 pmol of primers were heated to 80°C,
llowed to cool to 40°C within 30 min, and incubated at
0°C for 45 min. Reaction mixture and Superscript re-
erse transcriptase (Gibco Life Technologies, Eragny,
rance) were then added according to the manufactur-
r’s instructions, and the mixtures were further incubated
or 60 min at 40°C. cDNA preparations were denatured
ith 0.2 M NaOH for 10 min at 40°C; neutralized with 0.5
Tris–HCl, pH 7.5; precipitated overnight with ethanol;
nd resuspended in 30 ml of water. Each cDNA fragment
was then amplified with a pair of phosphorylated internal
primers corresponding to nt 25–11 and 405–424 for
fragment 1, nt 365–385 and 1100–1123 for fragment 2, and
nt 1022–1045 and 1257–1277 for fragment 3. PCRs were
carried out with 5 ml of the cDNAs, 45 pmol of each
rimer, and AmpliTaq Gold DNA polymerase (Perkin–
lmer Cetus, Norwalk, CT) according to the manufactur-
r’s instructions in a Perkin–Elmer Cetus thermocycler as
ollows: 10 min at 94°C, 35 cycles of 20 s at 94°C, 20 s
t 55°C, and 1 min 30 s at 72°C and then 8 min at 72°C.
CR products were purified by agarose gel electrophore-
is and ligated to pUC 19 (Biolabs) linearized with PvuII.
or each PCR product, 10 clones were amplified, and the
nserts, were sequenced using BigDye Terminator Cycle
equencing kit (Perkin–Elmer Cetus) according to the
anufacturer’s instructions. Sequences were analyzed
ith the ABI PRISM 377 DNA Sequencer (Perkin–Elmer
etus).
ite-directed mutagenesis
Substitutions in the PVR gene were introduced in
he expression vector pSV2PVRa (Koike et al., 1990),
containing the same cDNA sequence of human PVRa
as that expressed in IMR-32 cells (kindly provided by
A. Nomoto and S. Koike, Japan), with the QuikChange
Site-Directed Mutagenesis kit (Stratagene, La Jolla,
CA) and specific primers. Each substitution was intro-
duced with a pair of complementary oligonucleotides:
59-CGCCCAAGAAGCTGGGCACCTGGGTGG-39 and
59-CCACCCAGGTGCCCAGCTTCTTGGGCG-39 for the
A-to-G substitution at nt 115, 59-CACCATGCCGCGC-
CCAAGTCAGCTG-39 and 59-CAGCTGACTTGGGCGCG-
GCATGGTG-39 for the C-to-T substitution at nt 199, and
59-CAGCGAGGCATTCTGCAGCTCCGCG-39 and 59-CG-
CGGAGCTGCAGAATGCCTCGCTG-39 for the G-to-A sub-
titution at nt 311. Automated sequencing as described
ere was used to verify correct mutagenesis.
ell transfection
One-day-old subconfluent cultures of LM cells in 25-
m2 T-flasks were transfected with 1.5 mg of each of the
lasmids carrying the human PVR cDNA and 0.5 mg of
EXPRESSION OF MUTAThe plasmid pAG60 (Colbe`re-Garapin et al., 1981) carry-
ng a selective marker conferring resistance to the anti-
1iotic G418 (geneticin; GIBCO BRL, Gaithersburg, MD)
sing LipofectAMINE Plus reagent (GIBCO BRL) as de-
cribed by the manufacturer. Twenty-four hours after
ransfection, a selective medium containing a high dose
f G418 (690 mg/ml geneticin) was added to the cells to
elect for high expression of the transgenes. At 1 month
ost-transfection, the geneticin concentration was re-
uced to 370 mg/ml. G418-resistant colonies were either
pooled by trypsinization and PVR-positive cells were
selected by FACS or isolated and grown as cell clones.
PVR-positive clones were identified by FACS analysis.
The presence of mutations in the PVR mRNA of the pools
of cell colonies was verified by automated sequencing
after RT–PCR amplification as described earlier.
Immunofluorescence staining and FACS analysis
LM cell PVR transformants were trypsinized and im-
munofluorescence staining was performed to determine
the level of PVR expression on the cell surface. All
staining and washing steps were performed at 4°C in
staining buffer (SB) containing PBS with 1% filtered FCS
and 0.1% sodium azide. Cells (106 for fluorescence anal-
ysis and 2 3 107 for cell sorting) were incubated for 30
min on ice with 50 ml (for fluorescence analysis) or 500 ml
(for cell sorting) of anti-PVR monoclonal antibody (mAb)
404-19 (Lopez et al., 1999) (kindly provided by M. Lopez,
France) or 280 (Minor et al., 1984) (kindly provided by P.
Minor, United Kingdom). A mouse IgG1 k antibody (Sigma
Chemical, Poole, Dorset, UK) was used as a negative
control. Cells were washed once with 5 ml of SB and
incubated with a sheep anti-mouse IgG conjugated with
fluorescein isothiocyanate (Sanofi Diagnostic Pasteur,
Montpellier, France) for 30 min on ice. Cells were
washed once again as described above and resus-
pended in 500 ml (for fluorescence analysis) and 6 ml (for
ell sorting) of SB. Stained cells were then subjected to
ACS analysis with a Becton Dickinson (Le Pont de Claix,
rance) FACScalibur machine, and transformant LM
ells were sorted to obtain highly enriched PVR-positive
ultures. This procedure was repeated two or three
imes until the percentage of PVR-positive cells was
5–99%. Relative densities of PVR on the cell surface
ere evaluated by comparing the mean fluorescence per
ell for the various transformant LM cells stained with
he same antibody in the same assay. The level of PVR
xpression on the cell surface of LM/PVR mutants was
.5–3 times lower than that on LM cells expressing the
VR form of IMR-32 cells (LM/PVRIMR). These differences
ere similar with both anti-PVR antibodies used. We took
hese differences into account for experiments as indi-
ated here.
We tested for the viral antigen in the various transfor-
ant LM cells infected with PV1/Mahoney at an m.o.i. of
339LIOVIRUS RECEPTORS0 TCID50/cell. The cells were grown on coverslips, in-
fected, and fixed in 3% paraformaldehyde 2 or 24 h after
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3 IO ETinfection. The C3 mAb (Blondel et al., 1983), or a mouse
IgG1 k antibody (Sigma), was used for indirect immuno-
fluorescence, with a sheep anti-mouse IgG conjugated
with fluorescein isothiocyanate (Sanofi Diagnostic Pas-
teur), as described previously (Borzakian et al., 1992).
Uninfected cells were used as negative controls.
Resistance of cells to virus-induced lysis
LM-cell PVR-transformants (106) were seeded onto
wells of 24-well plates and infected 18 h later. At the
time of infection, cells were counted, and for each cell
type, the m.o.i. was adjusted to 10 TCID50/cell. After 30
min of adsorption at 37°C, cells were washed twice,
and 1 ml of DMEM containing 2% FCS was added to
each well. After 28 or 48 h of infection, the number of
adherent cells in infected wells was determined as a
percentage of that in uninfected wells using a Coulter
Counter (Beckman-Coulter). As previously found
(Calvez et al., 1995a), and verified here by trypan blue
exclusion, adherent cells in both infected and unin-
fected wells were alive. The percentage values ob-
tained therefore represent the percentages of cells
surviving infection.
Virus growth cycles
Duplicate 24-well plates containing cell monolayers
were infected at an m.o.i. of 10 TCID50/cell as described
arlier and incubated at 37°C for 1, 2, 4, 6, 8, or 24 h. At
ach time, extracellular virus was harvested, and the
orresponding cell-associated virus was recovered by
reezing and thawing the cells. The infectivity of clarified
irus suspension was determined by TCID50 assay.
reparation of radiolabeled virus
Virus was labeled with [35S]methionine (1400 Ci/mmol;
ICN, Orsay, France) and purified on cesium chloride
density gradient by isopycnic centrifugation as previ-
ously described (Blondel et al., 1983). The yield of mature
virions was measured optically, assuming 9.4 3 1012
particles/unit of optical density at 260 nm (Rueckert,
1976). The specific activity of radiolabeled virus was
8.25 3 1027 cpm/particle, and the particle/TCID50 ratio
as 300.
V binding assays
Cells in suspension were incubated with [35S]methi-
onine-radiolabeled virus in a total volume of 150 ml of
ce-cold DMEM–2% FCS on a side-to-side rocking plat-
orm at 4°C overnight. For LM/PVRIMR cells that express
he highest level of PVR, radiolabeled virus was added to
.5 3 106 cells (m.o.i. 5 40 TCID50/cell). For the LM/PVR
utants expressing a lower level of PVR, the same
40 PAVmount of radiolabeled virus was added, but the number
f cells was adjusted so as to have the same ratio ofirus to PVR molecules in each assay, according to the
ean fluorescence values obtained by FACS with anti-
VR mAb 404-19 or 280 before each binding experiment.
fter the adsorption period, unattached virus was re-
oved by two washes with ice-cold DMEM–2% FCS.
ell-associated radioactivity was then determined by
cintillation counting and is expressed as a percentage
f the radioactivity present in the inoculum.
V conformational alteration assays
Cells were trypsinized, washed with ice-cold
MEM–2% FCS, and then incubated with [35S]methi-
onine-radiolabeled virus in a total volume of 2 ml of
ice-cold DMEM–2% FCS on a side-to-side rocking plat-
form at 4°C for 2.5 h to synchronize the infection. For
LM/PVRIMR cells that express the highest level of PVR,
adiolabeled virus was added to 107 cells (m.o.i. 5 100
TCID50/cell) and as for the binding assay, the number of
ells was adjusted for LM/PVR mutants so as to have the
ame ratio of virus to PVR molecules in each assay. After
he adsorption period, unattached virus was removed by
wo washes with DMEM–2% FCS. Alteration was initi-
ted by adding 5 ml of DMEM–2% FCS preheated to
7°C, and cells were agitated for 15 or 40 min at 37°C.
ells were then washed twice with ice-cold DMEM–2%
CS and once with ice-cold PBS. Cells were pelleted,
esuspended in 450 ml of 140 mM NaCl, 50 mM Tris, pH
.0, and lysed by the addition of 50 ml of 140 mM NaCl,
50 mM Tris, pH 8.0, 10% Nonidet P-40, and 1% SDS, as
described previously (Calvez et al., 1995a). After incuba-
tion for 20 min on ice, the cell lysates were clarified by
centrifugation for 5 min in an Eppendorf centrifuge and
layered onto 15–30% (wt/vol) sucrose gradients prepared
in PBS, which were then centrifuged in a Kontron
TST41.14 rotor for 2 h at 40,000 rpm at 4°C. Gradients
were fractionated, and the radioactivity per fraction was
counted.
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